MENU
+Compare
RSLS
Stock ticker: NASDAQ
AS OF
Apr 10 closing price
Price
$0.57
Change
+$0.23 (+67.65%)
Capitalization
4.33M

RSLS ReShape Lifesciences Inc Forecast, Technical & Fundamental Analysis

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases... Show more

RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RSLS with price predictions
Apr 10, 2025

Momentum Indicator for RSLS turns positive, indicating new upward trend

RSLS saw its Momentum Indicator move above the 0 level on April 10, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The 10-day RSI Indicator for RSLS moved out of overbought territory on April 02, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RSLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RSLS broke above its upper Bollinger Band on April 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RSLS entered a downward trend on March 31, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.264) is normal, around the industry mean (23.728). P/E Ratio (0.000) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.038) is also within normal values, averaging (41.794).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RSLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RSLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of medical devices for the treatment of obesity

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1001 Calle Amanecer
Phone
+1 949 429-6680
Employees
40
Web
https://www.reshapelifesciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOI1.690.12
+7.64%
Oncology Institute (The)
VRAX0.88N/A
-0.51%
Virax Biolabs Group Limited
UVSP25.81-1.20
-4.44%
Univest Financial Corp
FIX337.40-19.37
-5.43%
Comfort Systems USA
PRCT50.73-3.95
-7.22%
PROCEPT BioRobotics Corp

RSLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RSLS has been loosely correlated with BIAF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RSLS jumps, then BIAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RSLS
1D Price
Change %
RSLS100%
+65.58%
BIAF - RSLS
56%
Loosely correlated
-10.48%
HSCS - RSLS
35%
Loosely correlated
+14.75%
GMED - RSLS
31%
Poorly correlated
-4.44%
AZTA - RSLS
30%
Poorly correlated
-10.39%
LFWD - RSLS
29%
Poorly correlated
-2.80%
More